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Abstract
Background: Renal insufficiency (RI) following ST-segment elevation acute myocardial infarction (STEMI) is
associated with a worse clinical prognosis. We investigated the impact of RI on long-term mortality in rural female
patients with STEMI and evaluated prognostic factors.
Methods: A prospective cohort study of 436 consecutive rural female patients who were successfully treated with
reperfusion therapy for STEMI between May 2009 and August 2011 in secondary care hospitals in Liaoning province
northeastern China and followed up for 2 years. Patients were divided into three groups by estimated glomerular
filtration rate (eGFR): Normal group, eGFR ≥90 mL/min/1.73 m2 (n = 233). Moderate group, eGFR 60–90 mL/min/
1.73 m2 (n = 108). RI group, eGFR <60 mL/min/1.73 m2 (n = 95). The primary outcome was 2-year mortality.
Results: During follow-up (mean 741 ± 118 days), the RI group had a significantly higher mortality than the other
groups (24.21 % vs. 6.87 % and 10.19 %, p < 0.001). The RI group had significantly higher hospital mortality (7.37 %
p = 0.045 vs. Normal group). RI increased the risk of hospital mortality (hazard ratio (HR) 1.832, 95 % CI 1.017–3.091,
p = 0.033), and increased the risk of 2-year mortality (HR 3.872, 95 % CI 2.004–6.131, p < 0.001). Multivariate analysis
showed eGFR <90 ml/min/1.73 m2 and age ≥75 years as independent predictors of mortality at 2 years. In detail
these were eGFR 60–90 ml/min/1.73 m2 with HR 2.081, 95%CI 1.250–2.842, p < 0.001; eGFR <60 ml/min/1.73 m2
with HR 3.872, 95%CI 2.004–6.131, p < 0.001; age ≥75 with HR 1.461, 95%CI 1.011–1.952, p = 0.024.
Conclusions: RI had a powerful correlation with long-term mortality for rural female patients with STEMI after
reperfusion therapy.
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Background
At present the incidence of chronic kidney disease is
rapidly increasing [1]. Nearly 30 % of patients with ST-
segment elevation acute myocardial infarction (STEMI)
have combined renal insufficiency (RI) [2]. Widely used
early reperfusion therapy, including emergency primary
percutaneous coronary intervention (PCI) or thrombolysis
therapy has beneficial effects for STEMI [3, 4]. How-
ever, RI following STEMI is associated with a worse
clinical prognosis [5–7], a 6 to 11-fold increase in
hospital risk of death [8], and a 1.76- to 6.18-fold 7-
month risk of death [6]. Unfortunately, most STEMI
patients with RI are excluded from randomized trials.
Renal insufficiency may lead to alteration in lipid me-
tabolism, vascular endothelial injury and dysfunction,
trigger the inflammatory response, coagulation and
oxidative stress and increase atherosclerosis, by the
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sympathetic, neurohormonal pathway and renin angioten-
sin aldosterone axis activation [9–11].
Most clinical studies into myocardial infarction involve
only a minority of female patients. For example women
accounted for 29.6 % of the total enrolled patients in the
Korea acute myocardial infarction registry study [7].
This is of concern because acute myocardial infarction
mortality is higher in females than males and while there
have been declines in the risk of death in men; the rate
in women remains fairly constant [12]. The risk of in
hospital mortality after primary PCI is also significantly
higher for females than males [13], and female patients
with STEMI show significantly greater death rates than
males [14], with younger females at much higher risk
than males of the same age [15].
In China the rates of mortality due to cardiac disease
are growing, and while they are highest in urban areas,
the rate in rural areas is increasing more rapidly [16].
Therefore, female patients with STEMI complicated by
RI who reside in rural areas are an often neglected
population that may be at high risk of death resulting
from their condition. Little is known of the impact of RI
on the prognosis in rural female patients with STEMI
regardless of reperfusion therapy in Liaoning province in
northeastern China.
The objective of this study was to determine the asso-
ciation between RI and the risk of death in STEMI pa-
tients successfully treated with PCI or thrombolytic
therapy. We hypothesized that RI would be associated
with higher 2-year mortality. The results of our pro-
spective cohort study provide convincing evidence of
this association in a real world situation.
Methods
Subjects
This was a prospective, multicenter study conducted at
16 hospitals in the Liaoning Province of northeast China
from May 2009 to August 2011. The 16 hospitals were:
First Affiliated Hospital, China Medical University; First
Affiliated Hospital, Dalian Medical University; Changtu
xian People’s Hospital; Fuxin Mongolian Autonomous
County People’s Hospital; Yixian People’s Hospital; Benxi
Steel Company Hospital; Fushun Coal Mining Adminis-
tration Hospital; Chaoyang Center Hospital; Fuxin Cen-
ter Hospital; Zhuanghe Center Hospital; Wafangdian
Center Hospital; Pulandian Center Hospital; Donggang
Center Hospital; Dashiqiao Center Hospital; Zhangwu
xian People’s Hospital; Kuandian xian Center Hospital.
This study was conducted in accordance with the declar-
ation of Helsinki, and was conducted with approval from
the Ethics Committee of China Medical University. Writ-
ten informed consent was obtained from all participants.
We enrolled 479 consecutive rural female STEMI pa-
tients from May 2009 to August 2011 from all of the
centers. The inclusion criteria were: (1) STEMI was di-
agnosed according to European Society of Cardiology
(ESC) criteria [3]; (2) it was the first time STEMI was di-
agnosed; (3) all patients were given primary PCI treat-
ment within 12 h or thrombolytic therapy within 6 h
after symptom onset. The exclusion criteria were: (1)
acute myocardial infarction patients with acute kidney
injury (AKI); (2) patients undergoing dialysis treatment.
(3) patients whose non-infarct-related artery was treated
during primary PCI; (4) PCI was undertaken after
thrombolytic therapy.
Acute renal failure was diagnosed by an increase in
serum creatinine levels of 50 % or an absolute increase
of ≥26.5 μmol/l in 48 h [17].
Demographic and basic clinical data were obtained
from all patients, which included age, gender, body mass
index and cardiovascular risk factors. Additional clinical
data including clinical laboratory tests, coronary imaging
data, therapeutic strategies and adverse cardiac events
were collected by trained personnel.
eGFR measurement
Kidney function was measured by estimated glomerular
filtration rate (eGFR), calculated using the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI)
Modification of Diet in Renal Disease (MDRD) equation
[18] [CKD-EPI formula If female and if serum creatinine
(Scr) ≤0.7 mg/dL:
CKD‐EPI ¼ 144 Scr mg=dLð Þ=0:7‐0:329
 0:993age yearsð Þ
If female and if Scr > 0.7 mg/dL:
CKD‐EPI ¼ 144 Scr mg=dLð Þ=0:7‐1:209
 0:993age yearsð Þ:
Renal insufficiency (RI) was defined as eGFR <60 mL/
min/1.73m2according to the Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines [19] eGFR were
calculated by the Scr examination results immediately
after admission.
The patients were divided into 3 groups based on their
eGFR values; the Normal group (high eGFR group,
eGFR ≥ 90 mL/min/1.73 m2, n = 233), the Moderate
group (middle eGFR group, 60 mL/min · m2 < eGFR
<89 mL/min/1.73 m2, n = 108) who had moderate RI,
and the RI group (low eGFR group, eGFR <60 mL/min/
1.73 m2, n = 95).
Successful PCI
PCI was considered to be successful if the infarct-related
artery residual stenosis was <10 %, and the Thrombolysis
in Myocardial Infarction (TIMI) flow level reached 3
[20]. All patients were estimated immediately after PCI.
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Successful thrombolytic therapy
1.5 million Units of urokinase were administrated to pa-
tients by intravenous infusion within 30 min for thrombo-
lytic therapy.
Thrombolytic therapy was considered successful if
more than 2 of 4 criteria were met [9]: ST segment re-
solved by ≥ 50 % by electrocardiogram (ECG) within 2 h,
chest pain disappeared within 2 h; reperfusion arrhythmia
occurred; serum myocardial enzyme peaks were detected
in advance.
Medication
All patients received the recommended standard man-
agement for STEMI, including 300 mg loading dose of
aspirin and clopidogrel after admission, aspirin, clopido-
grel, low-molecular-weight heparin, beta-blockers, statins
and angiotensin-converting enzyme (ACE) inhibitors/
angiotensin receptor antagonist (ARB) as appropriate. The
details of the medications are included in Appendix 1.
Definition of risk factors
Abnormal body mass index (BMI) was defined as BMI ≥
25 kg/m [2, 21]. Diabetes was diagnosed by previous
medical history or fasting glucose ≥ 7.0 mmol/L and/or
2 h plasma glucose level ≥11.1 mmol/l (measured after
75 g oral glucose load). Hypertension was diagnosed by
previous medical history or systolic blood pressure ≥
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg
after admission. Hypercholesterolemia was diagnosed by
previous medical history or low-density lipoprotein
(LDL) cholesterol ≥ 2.6 mmol/L and/or non high-density
lipoprotein (HDL) cholesterol ≥3.3 mmol/L. Definition
of contrast-induced nephropathy (CIN) was an increase
in serum creatinine ≥ 0.5 mg/dL, occurring 48 h after ex-
posure to contrast media [22]. Current smoker was de-
fined as smoking >300 cigarettes/year.
Outcomes
Major adverse cardiac events (MACE) included: death,
recurrent myocardial infarction, target vessel revasculari-
zation and stroke.
Key bleeding end points were analyzed on the basis of
global use of strategies to open occluded coronary arter-
ies (GUSTO) criteria [23].
CIN, contrast-induced nephropathy was defined as ei-
ther a greater than 25 % increase of serum creatinine or an
absolute increase in serum creatinine of 0.5 mg/dL [24].
Clinical examination and laboratory analysis
Patients underwent physical examination, ECG examin-
ation and fasting blood biochemical examination after ad-
mission including Scr, serum creatine kinase MB (CKMB),
and cardiac troponin I (cTNI). Patients were examined for
myocardial necrosis markers and by ECG once every 8 h
in 72 h, then every 24 h they were examined again. Blood
leukocyte counts were examined 24 h after admission and
echocardiography 48 h after admission.
To ensure the standard of data collection, laboratory
procedures, data management and coordination between
the multiples centers involved in the study was up to our
quality control all the clinicians involved in this study re-
ceived uniform training before the research began.
Follow up
The patients were followed up by telephone for 2 years;
once per year; by the same doctor.
Statistical method
Categorical data were expressed with absolute numbers
and percentages and analyzed using the χ2 test. Continu-
ous data with normal distribution were described with
mean and standard deviation (SD) and median and
interquartile range (IQR; 25th to 75th). Data among
groups were compared using ANOVA. Further Student–
Newman–Keuls (SNK) analyses were performed between
the three groups. Non-normally distributed data among
groups were compared using rank test.
Corresponding Kaplan-Meier curves with the log-
rank test were constructed. Univariate analysis of
eGFR, Scr, Microalbuminuria, age, gender, diabetes,
hypertension, hyperlipidemia, Killip class, heart rate
(HR), ejection fraction (EF), white blood cell (WBC)
counts, and medication treatment were performed to
determine the predictors for mortality. Multiple Cox
proportional hazard model was used to estimate asso-
ciations between significant factors identified in the
univariate analysis. Hazard ratios (HR) and 95 % confi-
dence intervals (CI) were calculated and p value <0.05
was considered statistically significant. All analyses
were performed using SPSS version 19.0 (SPSS Inc.,
Chicago, IL, USA).
Results
The flowchart showing inclusion of patients in the
study is presented in Fig. 1. In total 479 patients were
enrolled in the study, 24 from these were excluded in-
cluding 8 patients with incomplete data, 4 for whom
clinical data were incomplete and 4 whose laboratory
data were incomplete. Thus, 455 patients were included
and 19 patients were lost to follow up. Finally 436 pa-
tients were included in the study 233 in the Normal
group, 108 in the Moderate group, and 95 in the RI
group (Fig. 1).
Study sample and characteristics
The mean follow-up period was 741 ± 118 days. Among
the 436 individuals in the final cohort, the mean age was
67.52 years, and 35.78 % had diabetes (Table 1). Elderly
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patients and those with hypertension and diabetes
accounted for a high proportion of patients in the RI
group. Median symptom to door time, door to balloon
time and door to needle time were 183, 134 and 56 min,
respectively. In the three groups the mean ages were
61.11 ± 8.42 years in the Normal group, 64.08 ± 6.91 years
in the Moderate group and 75.57 ± 7.53 years in the RI
group with a significant difference between all of the
groups (p < 0.05). The diabetes rates were 29.61 % in the
Normal group, 37.96 % in the Moderate group and
48.42 % in the RI group with a significant difference be-
tween the Normal and RI groups (p < 0.05). The hyper-
tension rates were 32.19 % in the Normal group 44.44 %
in the Moderate group and 52.63 % in the RI group with
a significant difference between the Normal and RI
group (p < 0.05). There were higher proportions in the
RI group of Killip ≥ 2 at 21.05 % compared to 9.26 %
(p < 0.05) in the Moderate group and 9.01 %, (p < 0.05)
in the Normal group, longer hospital stay at 12.05 ±
5.74 days compared to 8.36 ± 5.11 days (p < 0.05) in
the Moderate group and 8.53 ± 4.78 days (p < 0.05) in
the Normal group, low EF values at 44.38 ± 13.05 %
compared to 48.92 ± 14.02 % (p < 0.05) in the Moder-
ate group and 50.11 ± 13.60 % (p < 0.05) in the Normal
group, high Scr values at 116.67 ± 59.01 mmol/l com-
pared to 85.47 ± 44.90 mmol/l (p < 0.05) in the Moder-
ate group and 78.12 ± 31.13 mmol/l (p < 0.05) in the
Normal group, and cTnI peak at 45.33 ± 15.26 ng/ml
compared to 30.19 ± 18.73 ng/ml (p < 0.05) for the
Moderate group and 31.06 ± 16.28 ng/ml for the Nor-
mal group (p < 0.05) (Table 1). There were 298 patients
who underwent primary PCI and 138 thrombolytic
therapy.
Clinical outcomes
The mortality rates of the patients in the Normal
group, Moderate group and RI group were 1.72 %,
3.7 %, and 7.37 %, respectively, during hospitalization.
Patients in the RI group had a significantly higher
mortality rate compared with Normal group during
hospitalization (p = 0.045). There were no significant
differences in RMI, TVR, stroke and bleeding be-
tween the three groups. In-hospital MACE developed
more frequently in the patients in the RI group
compared with Normal group (p = 0.022). But there
was no significant difference in the incidence of CIN
(Table 2).
A similar trend was observed during 1 year of follow
up after hospital discharge. Patients in the RI group had
a significantly higher mortality rate compared with those
in the Normal group (16.84 % v.s.4.29 %, p < 0.001), and
a significantly higher MACE rate compared with the
other two groups (p < 0.001) (Table 2).
During 2 years of follow up, patients in the RI group
had a significantly higher mortality rate compared with
the other two groups (24.21 % v.s. 6.87 % and 10.19 %, p <
0.001). There were no significant differences in recurrent
myocardial infarction (RMI), target vessel revasculariza-
tion (TVR), stroke and bleeding between the three groups.
Compared with the RI group respectively, the Moderate
group and the Normal group had higher MACE rates
Fig. 1 Flow chart of the selection of the study population and allocation into groups according to estimated glomerular filtration rate
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(36.11 % v.s. 22.32 %, 52.63 % v.s. 22.32 %, p < 0.001)
(Table 2).
During 2 years of follow-up, there were 1 case of mod-
erate bleeding and 4 cases of minor bleeding in the RI
group. There were 3 cases of minor bleeding in the other
two groups, respectively.
Risk factors of 2 year mortality
Variables were analyzed by univariate analysis for sig-
nificant factors for 2 year mortality and are presented
in Table 3, this suggested that eGFR of less than
90 ml/min/1.73 m2, may be a predictor of 2 year
mortality as both 60–90 ml/mim/ m2 eGFR and
eGFR <60 ml/min/1.73 m2 were significant (both p >
0.001). Age ≥75 years was another significant factor
(p = 0.049) as well as hypertension (p = 0.013), Killip
class ≥2 (p = 0.023), and EF <40 (p = 0.025). The
Kaplan–Meier survival curves are depicted in Fig. 2.
The survival rate of the RI group was significantly
lower than in the other two groups (log-rank test, p
< 0.001).
Multivariate analysis then identified eGFR <90 ml/min/
1.73 m2 and age ≥75 years as independent predictors of
mortality at 2 years. In detail these were eGFR 60–90 ml/
min/1.73 m2 with HR 2.081, 95%CI 1.250–2.842, p <
0.001; eGFR <60 ml/min/1.73 m2 with HR 3.872, 95%CI
Table 1 Baseline characteristics
Normal group (n = 233) Moderate group (n = 108) RI group (n = 95) χ2 /F p value
Age (years) 61.11 ± 8.42 64.08 ± 6.91a 75.57 ± 7.53ab 114.59 <0.001
BMI (kg/m2) 24.51 ± 4.49 24.03 ± 3.98 23.95 ± 5.08 0.721 0.486
Killip≥ 2 21 (9.01) 10 (9.26) 20 (21.05)ab 10.297 0.006
HR (bpm) 71.58 ± 23.40 73.29 ± 19.17 78.05 ± 25.18 2.823 0.061
Current smoker (%) 96 (41.20) 47 (43.52) 45 (47.37) 1.056 0.59
Diabetes (%) 69 (29.61) 41 (37.96) 46 (48.42)a 10.686 0.005
Hypertention (%) 75 (32.19) 48 (44.44) 50 (52.63)a 13.145 0.001
Hyperlipidemia (%) 79 (33.91) 36 (33.33) 29 (30.53) 0.799 0.671
Previous MI (%) 15 (6.44) 9 (8.33) 2 (2.11) 3.697 0.157
Previous PCI (%) 11 (4.72) 5 (4.63) 4 (4.21) 0.078 1
Previous stroke 2 (0. 86) 3 (2.78) 4 (4.21) 4.336 0.087
Peripheral vasculardisease (%) 3 (1.29) 1 (0.95) 1 (1.05) 0.261 1
Anterior and/or Lateral wall (%) 113 (57.08) 45 (41.67) 53 (55.79) 4.039 0.133
Inferior and/or Posterior wall 105 (45.06) 60 (55.56) 40 (42.11) 4.437 0.109
Maximum ST segment elevation (mm) 3.16 ± 1.27 2.95 ± 1.08 3.11 ± 1.33 1.072 0.345
Q wave 96 (41.20) 38 (35.19) 41 (42.11) 1.573 0.455
Symptom to door time (min)
Median (25–75th) 189.46 (130.51–392.26) 170.13 (110.50–337.12) 180.11 (104.39–387.25) 0.978 0.613
Door to balloon time (min)
Median (25–75th) 123.42 (91.35–210.92) 135.56 (80.49–198.55) 142.6 (98.53–228.11) 3.071 0.215
Door to needle time (min)
Median (25–75th) 58.21 (28.20–110.83) 50.55 (31.02–126.02) 63.48 (32.01–130.44) 4.335 0.114
Left ventricular ejection fraction (%) 50.11 ± 13.60 48.92 ± 14.02 44.38 ± 13.05ab 6.051 0.003
IABP use 3 (1.29) 5 (4.63) 1 (1.05) 3.882 0.143
Successful PCI 166 (71.24) 73 (67.59) 57 (60.00) 3.92 0.141
Successful thrombolysis 40 (17.17) 21 (19.44) 18 (18.95) 0.314 0.855
Serum creatinine (mmol/l) 78.12 ± 31.13 85.47 ± 44.90 116.67 ± 59.01ab 28.612 <0.001
Peak troponin (ng/ml) 31.06 ± 16.28 30.19 ± 18.73 45.33 ± 15.26ab 28.253 <0.001
Hospitalization days 8.53 ± 4.78 8.36 ± 5.11 12.05 ± 5.74ab 18.401 <0.001
BMI body mass index, HR heart rate, MI myocardial infarction, PCI percutaneous coronary intervention, IABP intra-aortic balloon pump
acompared to Group A, p < 0.05
bcompared to Group B, p < 0.05
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Table 2 Outcomes of patients according to eGFR group
Normal group Moderate group RI group χ2 p value
(n = 233) (n = 108) (n = 95)
In hospital
MACE 7 (3.00) 6 (5.56) 10 (10.53)a 7.664 0.022
death 4 (1.72) 4 (3.70) 7 (7.37)a 6.127 0.045
Recurrent MI 2 (0.86) 1 (0.93) 1 (1.05) 0.472 1
TVR 0 1 (0.93) 1 (1.05) 2.941 0.216
Stroke 0 0 0 NS
Bleeding 1 (0.43) 0 1 (1.05) 1.403 0.45
CIN 0 1 (0.93) 2 (2.11) 4.383 0.06
At 1-year follow-up
MACE 35 (15.02) 24 (22.22) 36 (37.89)ab 20.734 <0.001
death 10 (4.29) 8 (7.41) 16 (16.84)a 14.814 <0.001
Recurrent MI 9 (3.86) 4 (3.70) 3 (3.16) 0.117 1
TVR 12 (5.15) 9 (8.33) 12 (12.63) 5.519 0.063
Stroke 1 (0.43) 2 (1.85) 1 (1.05) 2.02 0.424
Bleeding 3 (1.29) 1 (0.93) 4 (4.21) 3.244 0.173
At 2-year follow-up
MACE 52 (22.32) 39 (36.11)a 50 (52.63)a 29.275 <0.001
death 16 (6.87) 11 (10.19) 23 (24.21)ab 20.227 <0.001
Recurrent MI 13 (5.58) 10 (9.26) 6 (6.32) 1.631 0.442
TVR 17 (7.30) 12 (11.11) 13 (13.68) 3.524 0.172
Stroke 3 (1.29) 3 (2.78) 3 (3.16) 1.919 0.391
Bleeding 3 (1.29) 3 (2.78) 5 (5.26) 4.275 0.109
eGFR estimated glomerular filtration rate, MI myocardial infarction, TVR target vessel revascularization, MACE major adverse cardiac events
acompared to Normal group, p < 0.05
bcompared to Moderate group, p < 0.05
Table 3 Univariate and multivariate analysis for prediction of 2-year mortality
Univariate Multivariate
HR 95%CI p value HR 95%CI p value
eGFR ml/min/1.73 m2
≥ 90 1 1
60–90 2.911 1.295–3.731 <0.001* 2.081 1.250–2.842 <0.001*
< 60 5.043 1.585–8.960 <0.001* 3.872 2.004–6.131 <0.001*
Age ≥75 1.368 1.023–1.909 0.049* 1.461 1.011–1.952 0.024*
Diabetes 1.332 0.727–1.936 0.251
Hypertension 1.241 1.032–1.453 0.013* 1.191 0.904–1.395 0.114
Hyperlipidemia 0.927 0.544–1.147 0.690
Killip≥ 2 1.593 1.032–2.301 0.023* 1.131 0.781–1.893 0.586
EF < 40 % 1.227 1.012–1.447 0.025* 0.905 0.451–1.060 0.647
CI confidence interval, eGFR estimated glomerular filtration rate, EF ejection fraction, HR hazard ratio
*p <0.05
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2.004–6.131, p < 0.001; age ≥75 with HR 1.461, 95%CI
1.011–1.952, p = 0.024.
Risk factors for in hospital mortality
All variables were also included into univariate analysis
to investigate the independent predictors for in hospital
mortality. The independent predictors of mortality in
hospital were eGFR <60 ml/min/1.73 m2 and Killip ≥ 2
(Table 4). Further analysis of the significant factors by
multiple cox proportional hazard modeling identified in-
dependent predictors of mortality. This showed that the
independent predictors of hospital mortality were eGFR
<60 ml/min/1.73 m2 [HR 1.832, 95 % CI 1.017–3.091, p
= 0.033] and Killip ≥ 2 [HR 1.340, 95 % CI 1.012–1.647,
p = 0.018].
Discussion
The aim of this study was to investigate the effect of RI
on the mortality of female rural patients with STEMI.
We demonstrated that the in hospitalization and 2-year
mortality in the RI group (<60 ml/min/1.73 m2) were
significantly higher than in the other two groups. And
RI (eGFR <60 ml/min/1.73 m2) was an independent pre-
dictor of in hospital and 2-year mortality in the female
STEMI patients after emergency reperfusion therapy.
Compared with the Normal group, there was a 1.8-fold
higher risk of death during hospitalization, and 3.9-fold
higher risk of 2-year mortality. In the Moderate group
(60–89 ml/min/1.73 m2), there was a 2.1-fold higher
risk of 2-year mortality. We found a decreased eGFR
was associated with a higher risk of death. Thus, RI
was associated with higher rates of death. The most
important finding of our study is that the inclusion of
RI in the risk model improves the risk in female pa-
tients with STEMI in rural areas. We demonstrated
hospitalization mortality in the RI group was 7.37 %.
Another reported study showed a similar mortality
rate of 7.69 % [25]. It has also previously been con-
firmed that RI is an independent risk factor for poor
prognosis in both the short and long term for female
STEMI patients [26].
Renal dysfunction is an independent risk factor for
death in patients with STEMI [27]. And patients with
renal dysfunction have been shown to have a 6 to 11-
fold higher in-hospital mortality rate compared to pa-
tients with normal renal function [8]. These patients
more commonly developed low left ventricular ejec-
tion fraction, higher Killip class, cardiogenic shock,
hemodynamic instability or malignant arrhythmia dur-
ing admission [28]. Previous studies have also found
that the risk of MACEs and cardiac death at both
Fig. 2 Kaplan-Meier curve survival analysis of the three groups of
patients to 2-year post treatment. A represents the Normal
group, B represents the Moderate group and C represents the
RI group
Table 4 Univariate and multivariate analysis for prediction of in hospital mortality
Univariate Multivariate
HR 95%CI p value HR 95%CI p value
eGFR ml/min/1.73 m2
≥ 90 1 1
60–90 0.942 0.653–1.131 0.670 0.865 0.586–1.390 0.220
< 60 2.655 1.147–4.238 0.003* 1.832 1.017–3.091 0.033*
Age ≥75 0.815 0.462–1.536 0.504
Diabetes 0.893 0.601–1.072 0.443
Hypertension 0.747 0.352–1.167 0.340
Hyperlipidemia 0.86 0.317–1.053 0.622
Killip≥ 2 1.446 1.009–2.090 0.047* 1.34 1.012–1.647 0.018*
EF < 40 % 0.871 0.592–1.017 0.317
CI confidence interval, eGFR estimated glomerular filtration rate, EF ejection fraction, HR hazard ratio
*p < 0.05
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1 month and 1 year increased with lower eGFR [5].
Thus, the results of our study are in agreement with
the previous research.
Comparison between the three groups showed that
there were higher proportions of Killip class ≥ 2, longer
hospital stay, low LVEF values, high serum creatinine
levels and cTnI peak in the RI group. The patients had
larger myocardial infarction area and worse heart func-
tion. These differences may be related to the high mor-
tality in the RI group. The Killip class is a useful
prognostic tool for predicting in hospital mortality [29],
and our results support this as the ≥ class 2 was also a
predictive factor for in hospital mortality by multivari-
ate analysis. Another recent study on RI in STEMI also
found a higher Killip class was found with RI, and
those patients also showed increased mortality with RI
[30]. That study identified that RI patients were more
likely to be female as well as older, and more likely to
have diabetes mellitus, and hypertension [30]. Our
study also identified age, diabetes and hypertension as
likely to be higher in the RI group. Increased Killip
score and lower LVEF were also significant in RI pa-
tients in a study evaluating the in-hospital outcome of
patients with acute STEMI [31]. The mean LVEF was
also decreased in the RI patients in our study. In terms
of the 2-year mortality risk factors the RI group was
found to be at much higher risk than the other two
groups in this study and the only other predictive fac-
tor was age ≥75 years. That was possibly an expected
result [32].
We found there were no long-term standardized medi-
cation regimens after hospital discharge in the RI group.
And dual antiplatelet therapy was used less in hospital
in this group. Underuse of antiplatelet therapy, ACE in-
hibitors, β-blockers and statins might also be related to a
reduced survival rate in patients with renal insufficiency
as discontinuation of cardiac medication is itself associ-
ated with increased risk of mortality [33]. This may be
another factor that is related to the high mortality in the
RI group.
Renal dysfunction was associated with a 3 fold in-
creased odds of discontinuation of antiplatelet drugs
in patients with PCI [34]. Reasons for shorter dur-
ation of antiplatelet therapy and discontinuation
observed in these studies and ours may include
bleeding events, scheduled invasive procedures, psy-
chiatric drug use, unemployment, patient choice and
non-adherence and other medical events not speci-
fied including earlier mortality. It had been reported
AMI patients with decreased GFR may receive less
aggressive evidence-based therapies as those normal
patients [35].
This study has some limitations as it was a prospect-
ive multicenter study with a limited sample size
because of the limited number of rural patients. In the
RI group the patients were not grouped further to
eGFR 30–60 ml/min/1.73 m2 and eGFR <30 ml/min/
1.73 m2 to provide information on the severity of RI.
We also were unable to provide a mean value of eGFR
for the groups in this study because some of the raw
data was lost, so we had to rely on the grouping ranges
for our analysis. We did not include a control group
without cardiac disease, to investigate whether these
results relating to RI and mortality would be similar in
a group of patients without STEMI. In addition, we did
not address the question of a relationship between car-
diac disease and kidney disease in these patients. Fur-
ther analysis of more pathophysiological factors such
as biomarkers for cardiac damage for example tropo-
nin would provide important information on the rela-
tionship between cardiac and kidney diseases.
Conclusions
In this real-world prospective multicenter study we
found among female rural patients with STEMI after
thrombolytic therapy or primary PCI therapy that RI
was an independent risk factor for in-hospital and long-
term mortality and was associated with poor prognosis.
RI could be one of the better indices for clinical risk
stratification.
Availability of supporting data
The data set supporting the results of this article are in-
cluded within the article.
Ethics approval and consent to participate
This study was conducted in accordance with the
declaration of Helsinki, and was conducted with ap-
proval from the Ethics Committee of China Medical






There were no significant difference in the adminis-
tration of aspirin, ACEI/ARB, statins, beta -blockers,
LWMH and traditional Chinese medicine between
the three groups. But clopidogrel and dual antiplate-
let therapy were lower in the RI group compared
with the Normal group during hospitalization. The
patients were followed up at 2 year. We found that
clopidogrel, dual antiplatelet therapy, ACEI/ARB, sta-
tins, b-blocker were less used,but traditional Chinese
medicine were more used in the RI group during
follow-up (Appendix 1).
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